| 價格 | 詢價 |
| 包裝 | 1removed |
| 最小起訂量 | 1removed |
| 發(fā)貨地 | 上海 |
| 更新日期 | 2026-08-03 |
| 中文名稱:化合物 Vistusertib | 英文名稱:Vistusertib |
| CAS:1009298-59-2 | 品牌: TargetMol |
| 產(chǎn)地: 美國 | 保存條件: Store at low temperature Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| 純度規(guī)格: 99.06% | 產(chǎn)品類別: 抑制劑 |
| 貨號: T001|T1961 |
| 名稱 | Vistusertib |
| 描述 | Vistusertib (AZD2014) is an orally bioavailable inhibitor of the mammalian target of rapamycin (mTOR) with potential antineoplastic activity. |
| 細胞實驗 | AZD2014 is prepared in DMSO (10 mM) and stored under nitrogen, and then diluted with appropriate media before use[1]. Cells are plated in 96-well plates for the indicated time. For CellTiterGlo assays: CellTiterGlo is mixed with the cells. Cells are normalized to day 0 control and net growth is determined using the following formula: ((x?y)/(z?y))=net growth, where x=reading of treated sample at end of study, y=average reading on day 0, and z=reading of DMSO-treated sample at end of study. The concentration of DMSO does not exceed 0.03% for any experiment. For MTS assays: adherent cell lines are grown in 96-well plates. MTS reagent is added on day 0 and on day 3 post-AZD2014 addition. Suspension lines are assayed using the Alamar Blue reagent, 72 hours after AZD2014 addition[1]. |
| 激酶實驗 | Recombinant truncated FLAG-tagged mTOR expressed in HEK 293 cells is used in biochemical assays, together with a biotinylated p70S6K peptide substrate. Streptavidin donor and protein A acceptor beads are used to assemble the capture complex for generation of the assay signal. The activity of the lipid kinases, PI3K alpha, beta, delta, and gamma are measured using recombinant proteins and the lipid PIP2 as substrate. Assays for ATM and DNA-PK activity are performed. The mTOR cellular activity is measured in MDAMB468 cells, using an Acumen laser scanning cytometer to analyze the levels of phosphorylation of S6 (Ser235/236) and AKT (Ser473)[1]. |
| 體外活性 | 在人類ER+乳腺癌移植模型中,AZD2014通過調(diào)控mTORC1和mTORC2底物,抑制腫瘤生長. |
| 體內(nèi)活性 | 在乳腺癌細胞系(抗激素療法的ER+細胞系)中,AZD2014抑制細胞生長,促使細胞凋亡。AZD2014能夠抑制mTORC2的生物標(biāo)記pAKTSer473和 pNDRG1Thr346。 |
| 存儲條件 | Store at low temperature Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| 溶解度 | DMSO : 50 mg/mL (108.1 mM), Sonication is recommended. H2O : < 1 mg/mL (insoluble or slightly soluble) Ethanol : < 1 mg/mL (insoluble or slightly soluble) 10% DMSO+90% Saline : < 5 mg/mL (10.81 mM), Lower concentrations may be soluble, but exact solubility limit is unknown. 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 5 mg/mL (10.81 mM), Solution. |
| 關(guān)鍵字 | Vistusertib | S6Kinase | S6 Kinase | pS6 (S235/236) | PI3Kα | P-Akt (S473) | mTOR | Mammalian target of Rapamycin | Inhibitor | inhibit | AZD-2014 | AZD 2014 | Autophagy | Apoptosis |
| 相關(guān)產(chǎn)品 | Urea | Formamide | Guanidine hydrochloride | Naringin | Aceglutamide | Alginic acid | Dextran sulfate sodium salt (MW 5000) | Hemin | Hydroxychloroquine | Stavudine | Paeonol | Ethyl linoleate |
| 相關(guān)庫 | 抑制劑庫 | 抗癌活性化合物庫 | 經(jīng)典已知活性庫 | 已知活性化合物庫 | 臨床失敗化合物庫 | 抗衰老化合物庫 | 高選擇性抑制劑庫 | 免疫/炎癥分子化合物庫 | 藥物功能重定位化合物庫 | 疼痛相關(guān)化合物庫 | 抗癌臨床化合物庫 | 抗癌藥物庫 |
| 成立日期 | 2013-04-18 (14年) | 注冊資本 | 566.2651萬人民幣 |
| 員工人數(shù) | 100-500人 | 年營業(yè)額 | ¥ 1億以上 |
| 主營行業(yè) | 化學(xué)試劑,生物活性小分子 | 經(jīng)營模式 | 貿(mào)易,試劑,定制,服務(wù) |
| 產(chǎn)品名稱 | 價格 | 公司名稱 | 報價日期 | |
|---|---|---|---|---|
| 詢價 |
VIP7年
|
上海澤葉生物科技有限公司
|
2026-08-03 | |
| 詢價 |
VIP2年
|
廣州佳途科技股份有限公司
|
2026-07-02 | |
| ¥583.90 |
VIP14年
|
上海阿拉丁生化科技股份有限公司
|
2026-06-23 | |
| ¥583.90 |
VIP3年
|
上海阿拉丁生化科技股份有限公司
|
2026-06-10 | |
| 詢價 |
上海嘉定區(qū)澄瀏公路52號
|
2025-11-06 | ||
| 詢價 |
南京百鑫德諾生物科技有限公司
|
2024-09-26 | ||
| ¥1200 |
深圳盛大醫(yī)藥科技有限公司
|
2023-03-15 | ||
| 詢價 |
匯聚化學(xué)(上海)有限公司
|
2022-02-24 |